Search Back New search Go to resultsDiseaseMain groupHematological Diseases, Non-MalignantProtocol groupAnemias, CytopeniasDiseaseThrombotic Thrombocytopenic PurpuraSubgroupICD10M31.1MeSHPurpura, Thrombotic ThrombocytopenicSequenceCAPL10, TTP, C1 (PID2111) -|- C2+ (PID2112)ChemotherapyChemo-substanceRituximabChemo-substanceRituximabChemo-substanceRituximabChemo-substanceRituximabNo. Substances1 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCaplacizumabDimetindenParacetamolPrednisoloneSupportive substanceBalanced Crystalloid SolutionCaplacizumabDimetindenParacetamolPrednisoloneSupportive substanceBalanced Crystalloid SolutionCaplacizumabDimetindenParacetamolPrednisoloneSupportive substanceBalanced Crystalloid SolutionCaplacizumabDimetindenParacetamolPrednisoloneNo. Substances14Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentiondisease controlRisksBleedingDyspneaEmetogenicity (MASCC/ESMO)HeadacheRash only studiesPublicationAuthorFakhouri FScully MDiseaseThrombotisch-thrombozytopenische Purpura, akut, mind. 18 J.TTP, älter 18 JahreOriginClinical Development, Ablynx, Zwijnaarde, Belgium, HERCULES investigatorsHopital Necker-Enfants Malades, ParisProtocols in Revision 3 protocols foundProtocols under revision.Caplacizumab 10, Thrombotic Thrombocytopenic Purpura, cycle 1 (PID2111 V1.0)Caplacizumab 10, Thrombotic Thrombocytopenic Purpura, cycle 2+ (PID2112 V1.0)Rituximab 375, thrombotic thrombocytopenic purpura (PID2865 V1.0)
